<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonpregnant reproductive-age patient with non-acute AUB: Initial management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonpregnant reproductive-age patient with non-acute AUB: Initial management</h1>
<div class="graphic"><div class="figure"><div class="ttl">Nonpregnant reproductive-age patient with non-acute AUB: Initial management</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm describes the management of nonpregnant reproductive-age patients with non-acute AUB; management of patients with acute AUB is discussed in related UpToDate content.</div><div class="graphic_footnotes"><p>AUB: abnormal uterine bleeding; NSAIDs: nonsteroidal antiinflammatory drugs; IUD: intrauterine device; LNG 52: 52 mg levonorgestrel-releasing IUD (Mirena or Liletta).</p>
<p>* Treatment of certain underlying conditions before initiating other therapy, if feasible, may correct the AUB or make further treatment more effective.</p>
<p>¶ Other progestin therapies (eg, DMPA, LNG 52) are not appropriate for treating patients with AUB who may wish to conceive in the next one to two years. NSAIDs may be used as an alternative, but should be discontinued upon conception.</p>
<p>Δ Estrogen therapy is contraindicated in some patients (eg, hypertension, history of venous thromboembolism or stroke, migraine with aura). This is discussed in related UpToDate content.</p>
<p>◊ While the LNG 52 is often appropriate for patients with contraindications to estrogen, some patients may decline, or have contraindications (eg, abnormalities of the uterine cavity, active pelvic infection) to the LNG 52. Treatment of such patients may include oral/injectable progestin therapy, noncontraceptive doses of estrogen-progestin therapy, or nonhormonal therapy (eg, NSAIDs, short-term use of tranexamic acid). Medical consultation is often helpful to determine thrombotic risk in selected patients. This is discussed in related UpToDate content.</p>
<p>§ High-dose oral or injectable progestin-only therapies may be used as an alternative to estrogen-progestin contraceptives or LNG 52 for selected patients; however, they often initially result in irregular menses and are associated with side effects (eg, dysphoria, bloating, increased appetite) that some patients find bothersome.</p>
¥ Both estrogen-progestin contraceptives and the LNG 52 are effective treatments for AUB, provide effective contraception, are well tolerated, and have a low risk of adverse effects. The choice between the two methods depends on several factors (eg, patient preference) and is discussed in related UpToDate content.</div><div id="graphicVersion">Graphic 138483 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
